Leona M. and Harry B. Helmsley Charitable Trust announced today it has awarded a $300,000 grant to Cure Alzheimer’s Fund.
Annual Awards Support “Tomorrow’s Leaders in Alzheimer’s Disease Research;”
Honor Legacies of Drs. George Glenner and Leon Thal
April 9, 2008 – A coalition of leading Alzheimer’s disease organizations today announced the first three recipients of “Tomorrow’s Leaders in Alzheimer’s Disease Research” prizes; a new award mechanism to recognize outstanding young scientists in Alzheimer’s and dementia research.
Dr. Rob Moir
Researcher Dr. Rob Moir, a member of the Cure Alzheimer's Fund Oligomer Collaborative, and researcher at Massachusetts General Hospital in Boston, presented research supported by Cure Alzheimer's Fund in March to the International Conference on Alzheimer's Disease/Parkinson's Disease that points to evidence that the Abeta peptide, acknowledged to be implicated in the cause of AD, may in fact be a "part of our evolutionary ancient innate immune system." The work is a collaboration between Dr. Moir, Dr. Rudy Tanzi, Chair of the Cure Alzheimer's Fund Research Consortium, and infectious disease expert, Dr. James Kirby (Harvard Medical School).
Read the entire article by AlzForum's Gabrielle Strobel >
A paper released on April 1, 2009, in the Journal of Neuroscience corroborates Prana’s strategy to treat Alzheimer’s disease patients.
Says Dr. Charles Glabe, an author of the paper and member of Cure Alzheimer’s Fund Research Consortium, “these results are very exciting news for understanding the mechanism of Alzheimer’s pathogenesis. They help elucidate the fundamental role of metal ions like zinc in causing the formation of Abeta oligomers which damage synapses.”
While this paper did not have Cure Alzheimer’s Fund support, nor has Cure Alzheimer’s Fund supported the work of Prana, an Australian biotech company, the concepts involved have been central to investigations by Cure Alzheimer’s Fund’s Oligomer Collaborative, of which Dr. Glabe has been a part. (See the Oligomer Collaborative on our website. ) Please note that Dr. Rudy Tanzi, Chair of the Cure Alzheimer’s Fund Research Consortium, is a founder of Prana and endorses its pursuit of therapeutic interventions through anti-Abeta oligomer drugs such as Prana’s PBT2.
Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients>
Terry Moran, ABC news correspondent, shares his personal story of facing Alzheimer’s and getting his DNA tested for the disease. This segment also features Cure Alzheimer’s Fund Research Consortium member Dr. Sam Gandy participating in an upcoming GQ article spotlighting “rock-star” Alzheimer’s scientists photographed with real rock stars including Sheryl Crow, Will I Am and members of Aerosmith. Look for the issue of GQ on newsstands May 15th.
Terry Moran's Moment of Truth on Nightline>
The Alzheimer's Study Group was established on July 11, 2007 under the auspices of the Congressional Task Force on Alzheimer’s Disease with the charge of creating a National Alzheimer's Strategic Plan to overcome America’s mounting Alzheimer's crisis.
The National Alzheimer's Strategic Plan was released at a hearing before the U.S. Senate Special Committee on Aging on Wednesday, March 25th at 10:30 a.m. EDT.
The Alzheimer’s Study Group Strategic Plan>
Cure Alzheimer’s Fund recognizes the significant work of the Alzheimer’s Study Group and appreciates the solid framework they developed for a strategic national plan. However, we also believe we must be more aggressive and ambitious in defining a research agenda and timelines for development of effective therapies in our battle against this devastating disease. The last two decades have shown that understanding the causes and genetic risk factors for Alzheimer’s is absolutely critical to determining the disease models on which effective treatments and a potential cure should be based.
Cure Alzheimer’s Fund’s Statement on the Alzheimer’s Study Group’s Strategic Plan>
Getting to a Cure
Why do we need a National Strategy?
- The cost of care for Alzheimer’s patients will overwhelm Medicare and Medicaid if not checked within the next few years.
- With funding from private and public sources heavily constrained, it is essential to make each research dollar count. There is enough consensus in the AD research community now to posit a direction for further research that will maximize resources and minimize the time to a cure.
The Alzheimer's Study Group Strategic Plan provides a solid framework for a strategic national plan to combat the growing crisis of Alzheimer’s disease. It is clear that all involved in this report worked hard to develop a comprehensive strategy for the treatment and care of the more than 5.2 million Americans already battling Alzheimer’s and the 10 million caregivers across the country grappling with the challenges of caring for a loved one with the disease.
The Alzheimer's Study Group Strategic Plan>
Cure Alzheimer's Fund proposes a National Research Strategy to accelerate progress toward a cure. The proposal builds on our own Research Roadmap, and provides a broader path to intervention by 2020.
We have shared this draft with selected members of Congress and their staffs, and with the staff of the Alzheimer's Study Group , a bipartisan effort co-chaired by Newt Gingrich and former Senator Bob Kerrey, and featuring others including Justice Sandra Day O’Connor, Harold Varmus and our own Henry McCance. It is our goal to work collectively with other funding organizations, the National Institutes of Health and related government agencies to avert the looming crisis of Alzheimer’s. If we can agree on the fundamentals of a national research strategy, we can save millions of lives and billions of dollars within the next decade.
Cure Alzheimer's Fund's National Research Strategy>
Q&A on National Research Strategy>
© 2005-2017 Cure Alzheimer's Fund. All rights reserved.